Introduction
The 15th Congress of the European Hematology Association (EHA), held in Barcelona, Spain, brought together hematology professionals from around the world to discuss and disseminate important clinical information. Highlights from select EHA clinical presentations are included in this newsletter.
Featured Content
• Lymphoma Update
• Leukemia Update
• Multiple Myeloma Update
Editors
Frederick R. Appelbaum, MD, bio | Susan O’Brien, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: July 19, 2010 | Expiration date: July 18, 2011
Target Audience
The intended audience for this initiative includes hematologists, medical oncologists, hematologist-oncologists, oncology specialty pharmacists, and oncology nurses charged with the care of patients with hematologic malignancies.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Discuss implications of updated efficacy and safety data for clinically available treatment options for patients with hematologic malignancies
- Describe the potential role of new therapeutic agents or strategies into clinical practice to improve remission and survival rates for patients with hematologic malignancies
- Describe the proposed mechanisms of action of new and emerging therapeutic agents in development for the management of patients with hematologic malignancies
- Differentiate treatment regimens based upon efficacy and toxicity parameters
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 0199-0000-10-023-H01-P). |
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 19, 2010 through July 18, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT
The editors wish to thank Sara Fagerlie, PhD, a paid employee of ECG, for assistance in writing this document. |
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Allos Therapeutics, Inc.,
Celgene Corporation, Genentech BioOncology & Biogen Idec, and
Onyx Pharmaceuticals, Inc.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Frederick R. Appelbaum, MD
No financial relationships to disclose
Susan O’Brien, MD
Consultant Fees
Allos Therapeutics, Inc., Calistoga Pharmaceuticals, Inc., Celgene Corporation,
Facet Biotech Corporation, Genentech, Inc., Genmab, Inc., Genta, Incorporated, GlaxoSmithKline, sanofi-aventis,
Sunesis Pharmaceuticals, Inc.,
Trubion Pharmaceuticals, Inc.
Grants/Research Support
Bayer HealthCare Pharmaceuticals, Inc., Biogen Idec, Bristol-Myers Squibb Company, Gemin X Pharmaceuticals, Genta, Incorporated, Genentech, Inc.,
Hana Biosciences, Inc., Lilly USA, LLC, Novartis
Other Financial
Biogen Idec, Gemin X Pharmaceuticals, Lilly USA, LLC
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net
|
